Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 DiabetesJOURNAL OF PERSONALIZED MEDICINEIF32023-04-271OAAI
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR A Post Hoc Analysis of the CREDENCE TrialCLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGYIF7.12023-03-313OA
Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 DiabetesCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52023-03-261OAAI
Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11C]TelmisartanCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-09-300OAAI
GMP Compliant Synthesis of [18F]Canagliflozin, a Novel PET Tracer for the Sodium-Glucose Cotransporter 2JOURNAL OF MEDICINAL CHEMISTRYIF6.82021-11-083OAAI
Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosisJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22014-12-0128OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向